It will be interesting to investigate how much the phenotype and severity of disease is linked to the MPN-related mutations—what is the impact of alteration in epigenetic regulators and spliceosomal machinery, and does the JAK2 mutation render the cell particularly vulnerable to the impact of subsequent mutations? This evidence concerns the gene JAK2 and myeloproliferative neoplasm.